A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 5,900 shares of FDMT stock, worth $61,419. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,900
Previous 73,300 91.95%
Holding current value
$61,419
Previous $2.34 Million 94.73%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$20.93 - $30.01 $314,598 - $451,080
-15,031 Reduced 17.04%
73,198 $1.54 Million
Q1 2024

May 15, 2024

BUY
$17.03 - $35.87 $1.19 Million - $2.5 Million
69,671 Added 375.42%
88,229 $2.81 Million
Q4 2023

Feb 14, 2024

SELL
$9.76 - $21.25 $1.22 Million - $2.65 Million
-124,662 Reduced 87.04%
18,558 $375,000
Q3 2023

Nov 14, 2023

BUY
$12.64 - $19.76 $1.57 Million - $2.46 Million
124,335 Added 658.38%
143,220 $1.82 Million
Q2 2023

Aug 14, 2023

BUY
$15.16 - $23.26 $212,437 - $325,942
14,013 Added 287.62%
18,885 $341,000
Q1 2023

May 15, 2023

BUY
$15.45 - $23.19 $75,272 - $112,981
4,872 New
4,872 $83,000
Q3 2022

Nov 14, 2022

SELL
$6.96 - $11.48 $713,281 - $1.18 Million
-102,483 Reduced 45.56%
122,459 $984,000
Q2 2022

Aug 15, 2022

BUY
$5.68 - $15.99 $1 Million - $2.82 Million
176,409 Added 363.48%
224,942 $1.57 Million
Q1 2022

May 16, 2022

BUY
$13.16 - $22.64 $219,192 - $377,091
16,656 Added 52.25%
48,533 $733,000
Q4 2021

Feb 14, 2022

BUY
$19.56 - $32.94 $352,881 - $594,270
18,041 Added 130.39%
31,877 $699,000
Q3 2021

Nov 15, 2021

SELL
$22.73 - $36.04 $306,309 - $485,675
-13,476 Reduced 49.34%
13,836 $373,000
Q2 2021

Aug 16, 2021

BUY
$22.2 - $42.29 $170,851 - $325,463
7,696 Added 39.23%
27,312 $657,000
Q1 2021

May 17, 2021

SELL
$35.94 - $52.67 $1.18 Million - $1.73 Million
-32,847 Reduced 62.61%
19,616 $851,000
Q4 2020

Feb 16, 2021

BUY
$38.43 - $47.36 $2.02 Million - $2.48 Million
52,463 New
52,463 $2.18 Million

Others Institutions Holding FDMT

About 4D Molecular Therapeutics, Inc.


  • Ticker FDMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,382,400
  • Market Cap $337M
  • Description
  • 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...
More about FDMT
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.